Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Financial Report: Charles River Laboratories | Contract Pharma

What are you searching for?

Sign in
Financial News

Financial Report: Charles River Laboratories

WIL Research and Oncotest acquisitions boost revenues

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Charles River Laboratories
 
3Q Revenues: $425.7 million (+22%)

3Q Earnings: $38.0 million (flat)

YTD Revenues: $1.2 billion (+20%)

YTD Earnings: $111.1 million (-6%)

Comments: Research Models and Services (RMS) revenues were $120.9 million in the quarter, up 3%. Discovery and Safety Assessment (DSA) revenues were $215.8 million, up 36% driven primarily by the acquisitions of WIL Research and Oncotest, which contributed 35% to DSA revenue growth. Revenue for the Manufacturing segment was $89.0 million, up 21% driven primarily by the Microbial Solutions and Biologics Testing Solutions businesses. The acquisitions of Blue Stream Laboratories, Celsis, and WIL Research’s contract development and manufacturing services contributed 10.5% to growth in the quarter.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters